INDICATION LEQEMBI® [ (lecanemab-irmb) 100 mg/mL injection for intravenous use] is indicated for the treatment of Alzheimer’s disease (AD). Treatment with LEQEMBI should be initiated in patients with ...

Dr. Eric K. Singhi shares his insights into the advantages of the subcutaneous formulation of Opdivo versus the IV version ...

Hydrochloride for Injection, USP in two vial sizes: 25 mg/1 mL and 50 mg/2 mL, further broadening PCC's increasing portfolio ...

Piramal Pharma share price gained 3.87 per cent at Rs 252.05 a piece on the BSE in Thursday’s intraday trade. This came after ...

Piramal Pharma said that its subsidiary Piramal Critical Care (PCC) has launched Chlorpromazine Hydrochloride for Injection in various strengths in the US market.

The launch of Chlorpromazine Hydrochloride for Injection, USP (25mg/1mL and 50mg/2 mL vials) is the latest in a series of ...

Eisai is seeking approval for an injectable version of Leqembi while Eli Lilly is developing a new injectable drug. These ...

Dr. Balazs Halmos discusses the significance of the approval of subcutaneous Opdivo and what this treatment formulation means ...

Biogen and Eisai have announced that the US Food and Drug Administration (FDA) has accepted a Biologics License Application ...

BioArctic announces US FDA accepts Eisai’s BLA for subcutaneous maintenance dosing of Leqembi: Stockholm Wednesday, January 15, 2025, 13:00 Hrs [IST] BioArctic AB (publ) announc ...

LEQEMBI® [ (lecanemab-irmb) 100 mg/mL injection for intravenous use] is indicated for the treatment of Alzheimer’s disease (AD). Treatment with LEQEMBI should be initiated in patients with mild ...